

1 **Rapid detection of SARS-CoV-2 B.1.1.529 (Omicron BA.1) variant by SYBR Green□based**  
2 **RT□qPCR**

3 Fadi Abdel-Sater<sup>1</sup>, Rawan Makki<sup>1</sup>, Alia Khalil<sup>1</sup>, Nader Hussein<sup>1</sup>, Nada Borghol<sup>1</sup>, Ziad Abi  
4 Khattar<sup>1</sup>, Aline Hamade<sup>1</sup>, Nathalie Khreich<sup>1</sup>, Mahoumd El Homs<sup>1</sup>, Hussein Kanaan<sup>1</sup>, Line  
5 Raad<sup>1</sup>, Najwa Skafi<sup>1</sup>, Fatima Al-Nemer<sup>1</sup>, Zeinab Ghandour<sup>1</sup>, Nabil El-Zein<sup>1</sup>, Mohamad Abou-  
6 Hamdan<sup>1</sup>, Haidar Akl<sup>1</sup>, Eva Hamade<sup>1</sup>, Bassam Badran<sup>1</sup>§, Kassem Hamze<sup>1</sup>.<sup>§</sup>

7 <sup>1</sup>Laboratory of Molecular Biology and Cancer Immunology (Covid 19 Unit), Faculty of science  
8 I, Lebanese University, Hadath, Beirut, LB 1003.

9

10 **Corresponding author:**

11 Kassem Hamze: Laboratory of Molecular Biology and Cancer Immunology (Covid 19 Unit),  
12 Faculty of Science I, Lebanese University, Hadath, Beirut, LB 1003; e-mail:  
13 [kassem.hamze@ul.edu.lb](mailto:kassem.hamze@ul.edu.lb), phone number: 0096170258296.

14 Bassam Badran: Laboratory of Molecular Biology and Cancer Immunology (Covid 19 Unit),  
15 Faculty of Science I, Lebanese University, Hadath, Beirut, LB 1003; e-mail:  
16 [bassam.badran@ul.edu.lb](mailto:bassam.badran@ul.edu.lb), phone number: 00961675642.

17

18 <sup>§</sup> Co-corresponding authors

19

20 **Abstract**

21 The COVID-19 pandemic is unceasingly spreading across the globe, and recently a highly  
22 transmissible Omicron SARS-CoV-2 variant (B.1.1.529) has been discovered in South Africa  
23 and Botswana. Rapid identification of this variant is essential for pandemic assessment and  
24 containment. However, variant identification is mainly being performed using expensive and  
25 time-consuming genomic sequencing. In this study we propose an alternative RT-qPCR  
26 approach for the detection of the Omicron BA.1 variant using a low-cost and rapid SYBR Green  
27 method. We have designed specific primers to confirm the deletion mutations in the spike (S  
28  $\Delta$ 143-145) and the nucleocapsid (N  $\Delta$ 31-33) which are characteristics of this variant. For the  
29 evaluation, we used 120 clinical samples from patients with PCR-confirmed SARS-CoV-2  
30 infections, and displaying an S-gene target failure (SGTF) when using TaqPath COVID-19 kit  
31 (Thermo Fisher Scientific, Waltham, USA) that included the ORF1ab, S, and N gene targets. Our  
32 results showed that all the 120 samples harbored S  $\Delta$ 143-145 and N  $\Delta$ 31-33, which was further  
33 confirmed by Whole genome sequencing (WGS) of 10 samples thereby validating our SYBR  
34 Green-based protocol. This protocol can be easily implemented to rapidly confirm the diagnosis  
35 of the Omicron BA.1 variant in COVID-19 patients and prevent its spread among populations,  
36 especially in countries with high prevalence of SGTF profile.

37

38 **Keywords:** Omicron variant, COVID-19 pandemic, SARS CoV-2, SYBR Green-based RT-  
39 qPCR

40

41

## 42        **1. Introduction**

43        The World Health Organization has declared the COVID-19 outbreak in China a global  
44        pandemic on March 2020. Since then, the causative agent, severe acute respiratory syndrome  
45        coronavirus 2 (SARS-CoV-2), has been extensively investigated, with more than 8,313,147  
46        million genomic sequences obtained and made freely available on the GISAID database on  
47        February 16, 2022. As the SARS-CoV-2 spreads over the globe, a natural process of random  
48        mutations and evolution continues (Habas et al., 2020, Li et al., 2020). In some circumstances, a  
49        mutation provides an evolutionary advantage for the virus, resulting in the emergence of a novel  
50        viral lineage that outnumbers previous forms. Many SARS-CoV-2 variants have emerged in  
51        various regions of the world, and five of them, Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1),  
52        Delta (B.1.617.2), and, most recently, Omicron (BA.1), have been designated as variants of  
53        concern (VOC) due to their increased transmissibility, virulence, and/or ability to evade  
54        immunity (Davies et al., 2021, Faria et al., 2021, Tagally et al., 2021, Otto et al., 2021, Cele et  
55        al., 2022, Planas et al., 2022). Because of its unusual mutational profile and rapid increase in  
56        prevalence, the Omicron variant, first found in South Africa and Botswana in November 2021,  
57        acquired its VOC classification within days, displacing pre-existing lineages in that country.  
58        Omicron has since surpassed pre-existing variants in Europe, the United States, and a number of  
59        other countries, causing a new worldwide outbreak. Omicron (BA.1) displays more than 55  
60        mutations in its genome, with 33 of them occurring only in the spike(S) protein among which  
61        three deletions ( $\Delta$ 69-70,  $\Delta$ 143-145,  $\Delta$ 211) and one insertion (ins214EPE). Also, the nucleocapsid  
62        (N) protein contains four mutations including one deletion  $\Delta$ 31-33, and three substitutions  
63        (P13L, R203K, G204R) (Planas et al., 2022, Callaway, 2021).

64 The rapid spreading of Omicron across the globe urge the need to establish a rapid and low-cost  
65 diagnostic tool that could quickly and efficiently detect and track it in order to initiate response  
66 and proper policy for pandemic containment. Until now, sequencing is considered as the gold-  
67 standard method for identifying SARS-CoV-2 variants. This method is accurate but time-  
68 consuming and expensive. Alternatively, rapid and low-cost RT-qPCR detection methods were  
69 proposed recently including the use of a range of primers specific for mutations common to  
70 VOCs (Abdel Sater et al., 2021, Corman et al., 2020, Borsova et al., 2021, Granato et al., 2021,  
71 Zelyas et al., 2021, Vega-Magana et al., 2021, Bedotto et al., 2021), or utilizing commercial kits  
72 such as TaqPath COVID-19 diagnostic tests (Thermo Fisher Scientific, Waltham, USA) that  
73 included the ORF1ab, S, and N gene targets. Some of the SARS-CoV-2 VOCs, Alpha (B.1.1.7)  
74 and Omicron (BA.1), generate dropout of the S-gene result in TaqPath kit, with positive results  
75 for the other targets (ORF1ab and N genes). This feature has been used as an indicator or  
76 screening method to identify these particular variants. The failure of the S-gene target is caused  
77 by a deletion mutation  $\Delta 69-70$  in the respective gene and is called the S-gene target failure  
78 (SGTF). Following the use of TaqPath kit, confirmation of the Omicron variant can be  
79 performed by specific RT-PCR assays targeting mutations that are characteristic to this variant  
80 (S  $\Delta 143-145$  and N  $\Delta 31-33$ ) with mutation-matched primers or probes, and identification  
81 through amplification and melting curve analyses (Dachert et al., 2021). However, at least a  
82 subset of samples should be further characterized by sequencing to increase the confidence and  
83 reliability of the obtained results [15].

84 In 16 February 2022, 1,200,309 Omicron sequences have been shared worldwide through the  
85 GISAID, among them 1,129,379 sequences belong to the BA.1 sub-variant (94,09%), and all  
86 harboring the S  $\Delta 143-145$  and N  $\Delta 31-33$  mutations. Consequently, we report here a low-cost

87 SYBR Green-based qPCR protocol for the rapid and specific detection of these two deletion  
88 mutations. We propose primer sets, specific to S  $\Delta$ 143-145, and N  $\Delta$ 31-33, that could be applied  
89 as a second step to confirm the diagnosis when the number and proportion of SGTF are steadily  
90 increasing when using the Applied Biosystems TaqPath RT-PCR COVID-19 kit (Thermo Fisher  
91 Scientific, Waltham, USA).

## 92 **2. MATERIALS AND METHODS**

### 93 **2.1. Clinical specimens**

94 220 clinical nasopharyngeal samples were collected and selected for this study from 03 to 22  
95 December. All these samples were previously tested for the presence of SARS-CoV-2 at the  
96 Laboratory of Molecular Biology and Cancer Immunology of the Lebanese University, using the  
97 Applied Biosystems™ TaqPath™ COVID-19 assay which targeted the RdRp, N and S genes.  
98 120 of these clinical samples were positive for SARS-CoV-2 by TaqPath kit with SGTF profile  
99 and 100 clinical samples were negative for SARS-CoV-2. Written informed consent was  
100 provided by all participants.

### 101 **2.2. RNA extraction and SARS-CoV-2 qRT-PCR**

102 RNA was extracted from 200  $\mu$ L of VTM from the clinical samples on Kingfisher flex  
103 purification system (Thermo Fisher) using MagMAX™ Viral/Pathogen Nucleic Acid Isolation  
104 Kit (Thermo fisher). Reactions were performed in a 20  $\mu$ L final volume reaction containing 5  $\mu$ L  
105 of extracted RNA. RT-qPCR was performed using QuantStudio 5 real-time PCR detection  
106 system (Thermo fisher) and TaqPath 2019-nCoV real-time PCR kit (Thermo fisher), which  
107 targeted the RdRp, N and S genes of SARS-CoV-2.

108 For the validation of Omicron variant in SARS-CoV-2 positive samples, total RNA was  
109 retrotranscribed into cDNA using iScript cDNA synthesis kit (BioRad), following the

110 manufacturer's recommended procedures. Quantitative RT-PCR was carried out using iTaq  
111 universal SYBR Green super mix (Bio Rad). Real-time PCR was performed using Bio Rad  
112 CFX96 Real-Time PCR Machine. The thermal cycling conditions used were as follows: 94 °C  
113 for 2 min, followed by 40 cycles of amplification at 94°C for 10 seconds, and 60°C for 1 minute.  
114 The reaction was completed by determining the dissociation curve of all amplicons.

### 115 **2.3. Primer design**

116 Primers were designed based on the full sequence of the Wuhan SARS-CoV-2 genome sequence  
117 from NCBI nucleotide database ([NC\\_045512](#)) and the full sequence of B.1.1.529 (BA.1) variant  
118 (EPI\_ISL\_6640917) from GISAID EpiCoV database (Fig 1). Bioinformatics tools were used to  
119 design and verify the SARS-CoV-2 specific primers. We validated our PCR primers *in-silico*  
120 with the PCR Primer-Blast tool which allows to investigate the amplification targets of primers  
121 to thereby ensuring adequate specificity. The primer sets used in this study were synthesized and  
122 delivered by Macrogen (Republic of Korea) (Table 1).

### 123 **2.4. Genome sequencing and lineage analysis**

124 Ten samples displaying the Omicron variant profile by RT-PCR analysis were selected for  
125 genome sequencing. Samples were sequenced using the Nanopore MinION methodology and  
126 consensus sequences were generated using the bioinformatics SOP (<https://artic.network/ncov-2019/ncov2019-bioinformatics-sop.html>) in Nanopolish mode. Sequences obtained were  
127 deposited in GISAID database under the accession numbers EPI\_ISL\_7651286 to  
128 EPI\_ISL\_7651289, EPI\_ISL\_11327269, EPI\_ISL\_11327268, EPI\_ISL\_11327263,  
129 EPI\_ISL\_11327262, EPI\_ISL\_11327252 and EPI\_ISL\_11327251, were collected from 03 to 06  
130 December 2021.

132

## 133 **3. Results**

134 Surveillance data, in the Laboratory of Molecular Biology and Cancer Immunology at the  
135 Lebanese University, revealed, the re-emergence of SGTF profile with a traveler coming from  
136 Abidjan on December 3, 2021. This sample was identified as Omicron BA.1 by whole genome  
137 sequencing. Since then, the number and the proportion of samples with SGTF profile were  
138 steadily increasing and have reached, as of January 10, approximately 95% of positive cases  
139 among passengers coming to Lebanon. This dramatic increase in SGTF percentage, suspected as  
140 Omicron BA.1 variant, urge the need for a rapid and accurate diagnostic tool to detect and track  
141 this variant. In this study, we developed a SYBR Green-based RT-qPCR assay for the detection  
142 of Omicron BA.1 variant. Our design was based on the differences in gene sequence from the  
143 original SARS-CoV-2 sequence (Fig. 1, Table 1).

144 The Omicron BA.1 contains several specific mutations that could potentially serve as a good tool  
145 for timely detection. These include a nine nucleotide deletions in the S gene  $\Delta$ 143-145, and other  
146 nine nucleotide deletions in the N gene  $\Delta$ 31-33. Accordingly, two groups of primers were  
147 designated. The first group detect the two mutations (spike del 143-145, and N del 31-33) was  
148 designed to detect these two mutations whereas, the second group (spike WT 143-145 and N WT  
149 31-33) was designed to detect variants not harboring these deletions. A last primer pair (spike  
150 control) was designed from within the S gene in a region common to all variants including  
151 Omicron, and was used as a control for cDNA synthesis and to ensure RNA integrity.

#### 152 **Calibration curve and limit of detection**

153 In order to validate their accuracy and efficacy, the newly designed primer set underwent  
154 optimization by testing them on a serial 10-fold dilution of cDNA template as follows: 50, 5, 0.5,  
155 0.05, 0.005, 0.0005 and 0.00005 ng/ $\mu$ l. All diluted samples were tested in triplicates by the gold

156 standard TaqMan RT- qPCR (TaqPath kit) and by our SYBR Green- based RT-qPCR protocol  
157 (Table 2).

158 A calibration curve was generated for all the primer sets listed in table 2, using the serial dilution  
159 results. Linear regression performed for these primers sets demonstrated strong correlation (Fig.  
160 2). A limit of detection (LOD) was determined for each primer set and identified as 0.0005  
161 ng/ $\mu$ L for the two sets (Table 2, Fig. 2), or with maximal Ct of 34.05 or 35.5 obtained by  
162 TaqMan and SYBR Green RT-PCR respectively, resulting in a highly sensitive detection.

163 Moreover, the specificity of our primers was investigated by three different ways: i) using 100  
164 clinical negative samples for SARS-CoV-2 by TaqPath kit; they did not manifest a signal when  
165 tested with such negative controls. ii) using *in silico* prediction analyses as described in the  
166 Material and Methods section, and iii) by WGS of 10 samples.

167 To avoid any false-positive signals resulting from nonspecific products or primer-dimers, a  
168 melting curve analysis was included at the end of each PCR assay to determine the specificity  
169 and efficiency of each RT-qPCR reaction. Accuracy of our primers to amplify single amplicon is  
170 represented as single peak in melting curves (Fig. 3).

### 171 **Clinical evaluation of Spike del 143-145 and N del 31-33 primer sets**

172 After full optimization of the newly designed primer sets and the verification of their sensitivity  
173 and specificity in our qPCR assay, they were employed on 120 clinical samples positive for  
174 SARS-CoV-2, collected between 03 and 22 December 2021, and which have displayed a Ct < 30  
175 with an SGTF profile, as revealed by the TaqPath kit. Our results showed that the spike control-  
176 gene amplicons were detected in all samples, providing evidence of cDNA synthesis and sample  
177 integrity preservation (Online Resource 1). Importantly, the S del 143-145-gene amplicons were  
178 detected in all the 120 samples, indicating the presence of the S  $\Delta$ 143-145 deletion and obviously



179 the absence of the amino acids 143, 144 and 145 in the spike protein of these samples (Online  
180 Resource 1). Similar results were obtained for the N del 31-33-gene, amplicons were also  
181 detected in all the 120 samples indicating the presence of the N  $\Delta$ 31-33 deletion and the absence  
182 of the amino acids 31, 32 and 33 in the nucleocapsid protein of these samples. The use of S WT  
183 143-145 and N WT 31-33 primers did not result in amplified product in any of the samples,  
184 thereby indicating that the S  $\Delta$ 143-145 and N  $\Delta$  31-33 deletions are located within the genomic  
185 region targeted by these two primer sets.

186 The amplification results obtained with spike del 143-145 and N del 31-33 primers were fully  
187 concordant with S WT 143-145 and N WT 31-33 primers, 100% of the SGTF samples harboring  
188 both S  $\Delta$ 143-145 and the N  $\Delta$  31-33 deletions (Online Resource 1).

189 Furthermore, ten of the S-negative samples were sequenced by WGS at the Microbial  
190 Pathogenomics Laboratory of the Lebanese American University (LAU) and sequences obtained  
191 were deposited in GISAID database under the accession number EPI\_ISL\_7651286 to  
192 EPI\_ISL\_7651289, EPI\_ISL\_11327269, EPI\_ISL\_11327268, EPI\_ISL\_11327263,  
193 EPI\_ISL\_11327262, EPI\_ISL\_11327252 and EPI\_ISL\_11327251. Sequence data analysis  
194 revealed that the ten samples belonged to the Omicron variant, while analyses of more sequences  
195 are in progress.

196

#### 197 **4. Conclusion**

198 The protocol we described herein is faster, simpler and more cost-effective than genome  
199 sequencing-based method. The uniqueness of the targeted mutations (S  $\Delta$ 143-145 and N  $\Delta$ 31-33)  
200 renders this protocol highly accurate and amply adequate to the early identification of the  
201 suspected samples as Omicron BA.1 when genome sequencing is unavailable. In conclusion, this

202 mutation-specific PCR assay would allow any laboratory having the ability to conduct PCR  
203 assays to rapidly and reliably screen for Omicron BA.1 among all SARS-CoV-2 positive samples  
204 with SGTF profile, in order to enhance surveillance capacity to identify cases and support  
205 decision making for interrupting transmission.

206

### 207 **Author contributions**

208 FAS and KH Conceived and designed the experiments. RM, AK, NH, NB, ZAK, AH, NK, HK, LR,  
209 NS, FAN, ZG, NEZ and EH Performed the molecular biology assays. KH and FAS Analyzed and  
210 interpreted the data. The first draft of the manuscript was written by KH, FAS and NH. ZAK,  
211 AH and NK commented on the first draft of the manuscript. All authors read and approved the  
212 final manuscript.

### 213 **Funding**

214 This work was supported by Grants from the Lebanese University.  
215

### 216 **Availability of data and materials**

217 We declared that materials described in the manuscript, including all relevant raw data, will be  
218 freely available to any scientist wishing to use them for non-commercial purposes, without  
219 breaching participant confidentiality.

### 220 **Ethics approval and consent to participate**

221 All presented cases or their legal guardian provided consent to data collection and use according  
222 to institutional guidelines.

### 223 **Consent for publication**

224 All presented cases or their legal guardian provided consent to publish according to institutional  
225 guidelines.

## 226 **Competing interests**

227 The authors declare no competing interests.

228

## 229 **References**

- 230 1. Habas, K., Nganwuchu, C., Shahzad, F., Gopalan, R., Haque, M., Rahman, S.,  
231 Majumder, A.A, Nasim, T., 2020. Resolution of coronavirus disease 2019 (COVID-  
232 19). Expert review of anti-infective therapy, 18(12), 1201-1211,  
233 <https://doi.org/10.1080/14787210.2020.1797487>.
- 234 2. Li, X., Wang, W., Zhao, X., Zai, J., Zhao, Q., Li, Y., Chaillon, A., 2020. Transmission  
235 dynamics and evolutionary history of 2019-nCoV. J Med Virol. 92(5):501-511. doi:  
236 10.1002/jmv.25701.
- 237 3. Davies, N.G., Jarvis, C.I., CMMID COVID-19 Working Group, Edmunds, W.J., Jewell,  
238 N.P., Diaz-Ordaz, K., Keogh, R.H., 2021. Increased mortality in community-tested cases  
239 of SARS-CoV-2 lineage B.1.1.7. Nature. 593 (7858):270-274. doi: 10.1038/s41586-021-  
240 03426-1.
- 241 4. Faria, N.R., Mellan, T.A., Whittaker, C., Claro, I.M., Candido, D.D.S., Mishra, S., et al.,  
242 2021. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil.  
243 Science. 372(6544):815- 21. <https://doi.org/10.1126/science.abh2644>
- 244 5. Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., et  
245 al., 2021. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature.  
246 592:438-443. <https://doi.org/10.1038/s41586-021-03402-9>

- 247 6. Otto, S.P., Day, T., Arino, J., Colijn, C., Dushoff, J., Li, M., Mechai, S., Van Domselaar,  
248 G., Wu, J., Earn, D.J.D., Ogden, N.H., 2021. The origins and potential future of SARS-  
249 CoV-2 variants of concern in the evolving COVID-19 pandemic. *Curr Biol.* 31(14):  
250 R918-R929. doi: 10.1016/j.cub.2021.06.049.
- 251 7. Cele, S., Jackson, L., Khoury, D.S., Khan, K., Moyo-Gwete, T., Tegally, H., et al., 2022.  
252 Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. *Nature.*  
253 602, 654–656. doi: 10.1038/s41586-021-04387-1.
- 254 8. Planas, D., Saunders, N., Maes, P., Guivel-Benhassine, F., Planchais, C., Buchrieser, J.,  
255 et al., 2022. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.  
256 *Nature.* 602, 671–675. doi: 10.1038/s41586-021-04389-z.
- 257 9. Callaway, E., Heavily mutated Omicron variant puts scientists on alert. *Nature.* 2021. doi:  
258 10.1038/d41586-021-03552-w.
- 259 10. Kannan, S., Shaik Syed Ali, P., Sheeza, A., 2021. Omicron (B.1.1.529) - variant of  
260 concern - molecular profile and epidemiology: a mini review. *Eur Rev Med Pharmacol*  
261 *Sci.* 25(24):8019-8022. doi: 10.26355/eurrev\_202112\_27653.
- 262 11. Abdel Sater, F., Younes, M., Nassar, H., Nguewa, P., Hamze, K., A rapid and low-cost  
263 protocol for the detection of B.1.1.7 lineage of SARS-CoV-2 by using SYBR Green-  
264 based RT-qPCR. *Mol Biol Rep.* 2021; 48(11):7243-7249. doi: 10.1007/s11033-021-  
265 06717-y.
- 266 12. Corman, V.M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D.K., et al.,  
267 2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro*  
268 *Surveill.* 25(14):20200409c. doi: 10.2807/1560-7917.ES.2020.25.3.2000045.

- 269 13. Boršová, K., Paul, E.D., Kováčová, V., Radvánszka, M., Hajdu, R., Čabanová, V.,  
270 Sláviková, M., Ličková, M., Lukáčiková, Ľ., Belák, A., Roussier, L., Kostičová, M.,  
271 Líšková, A., Maďarová, L., Štefkovičová, M., Reizigová, L., Nováková, E., Sabaka, P.,  
272 Koščálová, A., Brejová, B., Staroňová, E., Mišík, M., Vinař, T., Nosek, J., Čekan, P.,  
273 Klempa, B., 2021. Surveillance of SARS-CoV-2 lineage B.1.1.7 in Slovakia using a  
274 novel, multiplexed RT-qPCR assay. *Sci Rep.* 11(1):20494. doi: 10.1038/s41598-021-  
275 99661-7.
- 276 14. Granato, P.A., Kimball, S.R., Alkins, B.R., Cross, D.C., Unz, M.M., 2021. Comparative  
277 evaluation of the Thermo fisher TaqPath™ COVID-19 combo kit with the Cepheid  
278 Xpert® Xpress SARS-CoV-2 assay for detecting SARS-CoV-2 in nasopharyngeal  
279 specimens. *BMC Infect Dis.* 21(1):623. doi: 10.1186/s12879-021-06347-6.
- 280 15. Zelyas, N., Pabbaraju, K., Croxen, M.A., Lynch, T., Buss, E., Murphy, S.A., Shokoples,  
281 S., Wong, A., Kanji, J.N., Tipples, G., 2021. Precision response to the rise of the SARS-  
282 CoV-2 B. 1.1. 7 variant of concern by combining novel PCR assays and genome  
283 sequencing for rapid variant detection and surveillance. *Microbiology spectrum.* 9(1),  
284 e00315-21. doi: 10.1128/Spectrum.00315-21.
- 285 16. Vega-Magaña, N., Sánchez-Sánchez, R., Hernández-Bello, J., Venancio-Landeros, A.A.,  
286 Peña-Rodríguez, M., Vega-Zepeda, R.A., Galindo-Ornelas, B., Díaz-Sánchez, M.,  
287 García-Chagollán, M., Macedo-Ojeda, G., García-González, O.P., Muñoz-Valle, J.F.,  
288 2021. RT-qPCR Assays for Rapid Detection of the N501Y, 69-70del, K417N, and  
289 E484K SARS-CoV-2 Mutations: A Screening Strategy to Identify Variants with Clinical  
290 Impact. *Front Cell Infect Microbiol.* 11:672562. doi: 10.3389/fcimb.2021.672562.

- 291 17. Bedotto, M., Fournier, P.E., Houhamdi, L., Levasseur, A., Delerce, J., Pinault, L.,  
292 Padane, A., Chamieh, A., Tissot-Dupont, H., Brouqui, P., Sokhna, C., Azar, E., Saile, R.,  
293 Mboup, S., Bitam, I., Colson, P., Raoult, D., 2021. Implementation of an in-house real-  
294 time reverse transcription-PCR assay for the rapid detection of the SARS-CoV-2  
295 Marseille-4 variant. *Journal of Clinical Virology*. 139: 104814. doi:  
296 10.1016/j.jcv.2021.104814.
- 297 18. Dächert, C., Muenchhoff, M., Graf, A., Autenrieth, H., Bender, S., Mairhofer, H., Wrtil,  
298 P.R., Thieme, S., Krebs, S., Grzimek-Koschewa, N., Blum, H., Keppler, O.T., 2022.  
299 Rapid and sensitive identification of omicron by variant-specific PCR and nanopore  
300 sequencing: paradigm for diagnostics of emerging SARS-CoV-2 variants. *Med Microbiol*  
301 *Immunol.* 211: 71–77. doi: 10.1007/s00430-022-00728-7.
- 302
- 303
- 304

305 **Table 1:** List of primer sets. Deleted nucleotides are in bold.

<b>Target Gene</b>	<b>Primer Name</b>	<b>Primer sequence (5'-3')</b>
N	N WT 31-33 Forward	GTAACCAGAATGGAGA <b>ACGCA</b>
N	N del 31-33 Forward	ACTGGCAGTAACCAGAATGGTG
N	N Reverse	CGGTAGTAGCCAATTTGGTCATC
S	Spike WT 143-145 Forward	ATGATCCATTTTTGG <b>GTGTTTATT</b>
S	Spike del 143-145 Forward	GTAATGATCCATTTTTGGACCA
S	Spike Reverse	ACACAAATTCCTAAGATTTTTGA
S	Spike control Forward	CAACAAAAGTTGGATGGAAAGTG
S	Spike control Reverse	GATCACGCACTAAATTAATAGGC

306

307

308 **Table 2.** Determination of the sensitivity by 7 serials 10-fold dilutions. Diluted samples were  
 309 tested by our SYBR Green- based protocol and by TaqMan RT- qPCR (TaqPath kit).

Concentration of DNA Dilution Factor 1/10	CT values (SYBR Green)			Ct values (Taq Path kit, S probe)
	Spike del 143-145	N del 31-33	S control	
50 ng/μl	19.51	19.43	19.07	17.73
5 ng/μl	21.89	21.59	21.42	20.79
0.5 ng/μl	24.99	25	24.65	24.05
0.05 ng/μl	28.58	28.69	28.34	27.89
0.005 ng/ul	30.94	32.1	33.52	31.61
0.0005ng/ul	35.56	35.4	34.32	34.05
0.00005ng/ul	ND	ND	ND	ND

310 ND: Not Detected.

311



312 **Figure Legends**

313

314 **Fig 1.** The Localization and design of the primers used. The nine nucleotides deleted in S gene  
315 and in N gene of Omicron variant are marked in bold.




316


317 **Fig 2.** Calibration curves of SYBR Green-based qPCR primers Spike del 143-145, N del 31-33,  
318 S control and TaqPath kit. Serially 10-fold diluted cDNA containing the mutations S  $\Delta$ 143-145  
319 and N  $\Delta$ 31-33 were amplified and analyzed. a) The threshold cycle (Ct) mean values were  
320 plotted against the Log starting quantity (ng/ $\mu$ l). slope, R<sup>2</sup> and Eff were determined. Each  
321 dilution was assayed in triplicate.

322

323 **Fig 3.** The melting curves for the products amplified with the SYBR Green-based qPCR protocol  
324 in S-gene target failure samples using the primers: a) Spike del 143-145; b) N del 31-33 and c)  
325 Spike control, reveal specific melt peak for each primer set.


326

**a****b****c**




**E=99.6%    R<sup>2</sup>=0.991    Slope= -3.336    Spike del (143,145)**  
**E=101.5%    R<sup>2</sup>= 0.976    Slope= -3.28    Spike control**  
**E=101.9%    R<sup>2</sup>=0.995    Slope= -3.278    N del (31-33)**  
**E=99.1%    R<sup>2</sup>=0.997    Slope= -3.368    TaqPath kit**


Spike WT 143-145



Spike del 143-145



N WT 31-33



N del 31-33

